Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs iShares MSCI Australia ETF (EWA) Price & Performance

BioNTech SE - ADRTrade
iShares MSCI Australia ETFTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs iShares MSCI Australia ETF — how do they compare? BioNTech SE - ADR trades at $92.64 (market cap $23.31B), while iShares MSCI Australia ETF trades at $29.94. The key difference: iShares MSCI Australia ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.

BNTXEWA
Market Cap
$23.31B
Sector
HealthBroad Market / Factor
52-Week High
$119.34$30.41
52-Week Low
$83.89$24.95
Enterprise Value
$6.60B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $93.67, up 2.72% today, with a bullish technical signal and strong analyst support. The stock faces fundamental challenges, including declining COVID-19 vaccine revenue and negative profitability, but holds a robust cash position of $16.78 billion. Recent news highlights leadership changes and pipeline advancements in oncology, with a consensus price target of $121.00 implying significant upside potential.

Outlook: Long-term growth hinges on oncology pipeline success, but near-term risks from vaccine demand volatility and net losses persist. Investment opportunity lies in discounted valuation relative to cash and pipeline assets, though execution risks and competitive pressures require careful monitoring.

iShares MSCI Australia ETF

EWA trades at $30.41, up 0.83% with a bullish technical bias from moving averages, though oscillators signal caution with RSI levels above 70 indicating potential overbought conditions. The stock shows strong momentum with ADX readings above 36, while support and resistance cluster near $30-$31. Recent corporate actions include a scheduled dividend of $0.40 per share for June 2026.

Outlook remains positive given technical strength, but elevated RSI warrants monitoring for pullbacks. Risks include macroeconomic sensitivity and sector competition. Investment appeal hinges on sustained earnings growth and dividend stability, with current levels offering limited upside near resistance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About iShares MSCI Australia ETF

EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.

Read more on EWA